Aligos Therapeutics “announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta agonist, in metabolic-dysfunction associated steatohepatitis, or MASH, subjects on Thursday, September 19, 2024 prior to the market open.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics initiated with a Buy at H.C. Wainwright
- Aligos Therapeutics trading halted, news pending
- Aligos Therapeutics announces 1-for-25 reverse stock split